Ki67 is a nuclear protein expressed in proliferating cells, which is detected by a primary monoclonal rabbit anti-human Ki67 antibody (clone 30-9). Ki67 expression level is determined by the percentage of appropriately stained tumor cells.

Consultation by a Genoptix Hematopathologist on previously diagnosed cases. We require appropriate clinical data and slides, as well as the most recent morphology report and laboratory test results.

When serial or subsequent COMPASS® evaluations are requested on the same patient and deemed clinically appropriate by a Genoptix Hematopathologist, Genoptix will automatically provide a CHART® report, unless otherwise indicated by the ordering physician. CHART® includes all medically necessary technologies, and a consultative review and correlation with relevant prior findings and intervening treatment by a Genoptix Hematopathologist.

The THxID® BRAF Mutation Analysis assay is for the qualitative detection of the BRAF V600E and V600K mutations in DNA samples extracted from formalin-fixed paraffin embedded (FFPE) melanoma tissue. It is intended to be used as an aid in selecting melanoma patients whose tumors carry the BRAF V600E mutation for treatment with dabrafenib, and as an aid in selecting melanoma patients whose tumors carry the BRAF V600E or V600K mutation for treatment with trametinib.
THXID® is a registered trademark of bioMerieux.

There are key genes that are recurrently mutated in various human cancers. Genomic DNA is isolated from bone marrow, aspirates, peripheral blood or formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the ABL1, ABL2, AKT1, AKT2, AKT3, ALK, APC, AR, ARAF, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, ATRX, AXL, B2M, BAP1, BCL2, BCL2L11, BCL6, BCOR, BIRC3, BRAF, BRCA1, BRCA2, BTK, CALR, CARD11, CBL, CCND1, CCND2, CCND3, CCNE1, CD274, CD33, CD79A, CD79B, CDH1, CDK2, CDK4, CDK6, CDKN1B, CDKN2A, CDKN2B, CEBPA, CHD1, CHEK2, CIC, CIITA, CREBBP, CRLF2, CSF1R, CSF3R, CTCF, CTNNB1, CXCR4, DAXX, DDR2, DDX3X, DDX41, DIS3, DNMT3A, EBF1, EGFR, EGR1, EIF1AX, EP300, EPCAM, EPHA2, EPOR, ERBB2, ERBB3, ERBB4, ESR1, ETNK1, ETV6, EWSR1, EZH2, FAM46C, FAS, FAT1, FBXW7, FGF19, FGFR1, FGFR2, FGFR3, FLT1, FOXO1, FUBP1, GAB2, GATA2, GATA3, GNA11, GNA13, GNAI2, GNAQ, GNAS, GNB1, H3F3A, HIF1A, HIST1H1E, HNF1A, HRAS, ID3, IDH1, IDH2, IGF1R, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KDR, KEAP1, KIT, KLF2, KRAS, MALT1, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K14, MAP3K9, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MET, MITF, MLH1, KMT2D, MPL, MSH2, MSH6, MTOR, MYC, MYCN, MYD88, NF1, NF2, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, P2RY8, PALB2, PBRM1, PDGFRA, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, PMS2, POLE, POT1, PPM1D, PRDM1, PRPS1, PTCH1, PTEN, PTPN11, RAC1, RAD21, RB1, REL, RET, RHEB, RHOA, RICTOR, RIPK1, RIT1, RNF43, ROS1, RPS15, RUNX1, S1PR2, SAMHD1, SETBP1, SETD2, SF3B1, SGK1, SH2B3, SMAD4, SMARCB1, SMC1A, SMC3, SMO, SOCS1, SOX2, SPEN, SPOP, SRSF2, STAG2, STAT3, STAT5B, STAT6, STK11, TBL1XR1, TCF3, TERT, TET2, TGFBR1, TGFBR2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, TSC1, TSC2, U2AF1, UBR5, VHL, WT1, XPO1, ZFHX4, ZMYM3, and ZRSR2 genes is determined using next-generation sequencing (NGS) technology.
NexCourse® is a registered trademark of Genoptix, Inc.

Polymerase chain reaction (PCR) and subsequent fragment analysis of paired normal and tumor tissue is used to determine microsatellite instability (MSI). Results are reported as MSI-H (at least two markers are unstable) or MSS (less than two markers are unstable).

There are several key genes recurrently mutated in melanoma. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the BRAF, CD274, CDK4, HRAS, KIT, KRAS, NF1, and NRAS genes is determined using next-generation sequencing (NGS) technology.

There are several key genes recurrently mutated in lung cancer. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the ALK, BRAF, CD274, EGFR, ERBB2, KRAS, and MET genes is determined using next-generation sequencing (NGS) technology.

The Therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Roto-Gene® Q MDx instrument for the detection of seven somatic mutations in codons 12 and 13 (exon 2) of the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue.

There are key genes recurrently mutated in colorectal cancer. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the BRAF, KRAS, and NRAS genes is determined using next-generation sequencing (NGS) technology.